• Platform
  • Programs
    • Pipeline
    • FORE-8394
  • Patients
    • FORE-8394 explained
  • Clinical Trials
    • FORE-8394
  • About
    • Leadership
    • News
    • Publications
    • Blog
Menu
  • Platform
  • Programs
    • Pipeline
    • FORE-8394
  • Patients
    • FORE-8394 explained
  • Clinical Trials
    • FORE-8394
  • About
    • Leadership
    • News
    • Publications
    • Blog
contact
  • Platform
  • Programs
    • Pipeline
    • FORE-8394
  • Patients
    • FORE-8394 explained
  • Clinical Trials
    • FORE-8394
  • About
    • Leadership
    • News
    • Publications
    • Blog
Menu
  • Platform
  • Programs
    • Pipeline
    • FORE-8394
  • Patients
    • FORE-8394 explained
  • Clinical Trials
    • FORE-8394
  • About
    • Leadership
    • News
    • Publications
    • Blog
contact

News

Fore Biotherapeutics Appoints Matthew E. Ros as Chief Executive Officer
Read More →
Fore Biotherapeutics Continues to Build Leadership Team with Executive and Board Appointments
Read More →
Fore Biotherapeutics Strengthens Leadership Team with Executive and Board Appointments
Read More →
Fore Biotherapeutics Opens U.S. Headquarters in Philadelphia’s Biotech Hub
Read More →
Fore Biotherapeutics Enters Pharma Business With BRAF Inhibitor as Lead Product
Read More →
High MAPK Activity May Predict MEK Inhibitor Benefit for RAS-Mutated Cancer Patients, Study Finds
Read More →
NovellusDx Registers Another Patent on their FACT™ system,Publishes a New Study With Guardent Health and MD Anderson InCancer Discovery; Was Selected To Present At BioMed, BIO 2017 andASCO
Read More →
Novellus Executes Exclusive Worldwide License Agreement withPlexxikon for PLX8394, Plexxikon’s Next-Generation, Clinical StageBRAF Inhibitor
Read More →
Novellus Closes $57M Series C Financing
Read More →
New partnership between Christiana Care’s Gene Editing Institute and NovellusDx speeds progress toward personalized cancer medicine
Read More →
Fore Biotherapeutics
3675 Market Street
Philadelphia, PA 19104
Linkedin Twitter

267-641-7575

info@fore.bio

© Fore Biotherapeutics Inc. 2021
Menu
  • Home
  • Platform
  • Programs
    • Pipeline
    • FORE-8394
  • Patients
    • FORE-8394 Explained
  • Clinical Trials
    • FORE-8394 Clinical Trial
  • About
    • Leadership
    • News
    • Publications
    • Blog
  • Contact